142374-16-1

Basic information

• Product Name: 2-(S)-amino>-3-<4-<<piperidin-4-yl>propyl>oxy>phenyl>propionic acid
• Synonyms: 2-(S)-amino>-3-<4-<<piperidin-4-yl>propyl>oxy>phenyl>propionic acid
• CAS NO: 142374-16-1
• Molecular Weight: 540.657
• Mol File: 142374-16-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(S)-amino>-3-<4-<<piperidin-4-yl>propyl>oxy>phenyl>propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(S)-amino>-3-<4-<<piperidin-4-yl>propyl>oxy>phenyl>propionic acid(142374-16-1)
• EPA Substance Registry System: 2-(S)-amino>-3-<4-<<piperidin-4-yl>propyl>oxy>phenyl>propionic acid(142374-16-1)

Safety Data

• Hazardous Substances Data: 142374-16-1(Hazardous Substances Data)

Upstream product

• 142374-14-9 4-(3-iodo-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 156185-63-6 N-Boc-piperidin-4-yl-propanol 
• 2629-72-3 4-(3-Hydroxypropyl)pyridine 
• 7037-49-2 3-(piperidin-4-yl)propan-1-ol 
• 1164-16-5 Z-L-Tyr-OH 
• 164149-27-3 tert-butyl 4-(3-bromopropyl)piperidine-1-carboxylate 
• 142374-15-0 methyl 2-(S)-amino>-3-<4-<<piperidin-4-yl>propyl>oxy>phenyl>propionic acid ester 

Downstream Products

• 403857-13-6 4-(3-{4-[2-(butane-1-sulfonylamino)-2-carboxy-ethyl]-phenoxy}-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 403857-17-0 3-(2-{(S)-2-(Butane-1-sulfonylamino)-3-[4-(3-piperidin-4-yl-propoxy)-phenyl]-propionyloxy}-4,6-dimethoxy-phenyl)-3-methyl-butyric acid 
• 403857-16-9 4-[3-(4-{2-(butane-1-sulfonylamino)-2-[2-(2-carboxy-1,1-dimethyl-ethyl)-3,5-dimethoxy-phenoxycarbonyl]-ethyl}-phenoxy)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 403857-15-8 4-{3-[4-(2-(butane-1-sulfonylamino)-2-{2-[3-(tert-butyl-dimethyl-silanyloxy)-1,1-dimethyl-propyl]-3,5-dimethoxy-phenoxycarbonyl}-ethyl)-phenoxy]-propyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 142408-92-2 methyl 3-(S)-amino>-4-<4-<<piperidin-4-yl>propyl>oxy>phenyl>butanoate 
• 1026303-40-1 4-(3-{4-[(S)-2-(Butane-1-sulfonylamino)-3-methoxycarbonyl-propyl]-phenoxy}-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 142408-93-3 4-{3-[4-((S)-2-Benzyloxycarbonylamino-3-carboxy-propyl)-phenoxy]-propyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 1025988-45-7 4-(3-{4-[(S)-2-(Butane-1-sulfonylamino)-3-carboxy-propyl]-phenoxy}-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1027603-46-8 4-{3-[4-((S)-2-Amino-3-methoxycarbonyl-propyl)-phenoxy]-propyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 403857-12-5 4-{3-[4-(2-amino-2-carboxy-ethyl)-phenoxy]-propyl}-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Synthesis of cyclic prodrugs of Aggrastat and its analogue with a modified phenylpropionic acid linker

(formula presented) 1a, n=2; 1b, n=1 The objective of this work was to synthesize cyclic prodrugs 1a and 1b from Aggrastat 2a and its analogue 2b, respectively, to improve their membrane permeation. Cyclic prodrugs 1a and 1b were formed using an ester bond between the -COOH group of Aggrastat or its analogue and the phenylpropionic acid linker 3 and an amide bond between the piperidinylamine and the -COOH group of the linker 3, respectively, as outlined in Scheme 4.

Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp

Inhibitors of platelet-fibrinogen binding offer an opportunity to interrupt the final, common pathway for platelet aggregation.Small molecule inhibitors of the platelet fibrinogen receptor GPIIb/IIIa were prepared and evaluated for their ability to prevent platelet aggregation.Compound 23m (L-700, 462/MK-383) inhibited in vitro platelet aggregation with an IC50 of 9 nM and demonstrated a selectivity of >24000-fold between platelet and human umbilical vein endothelial cell fibrinogen receptors.Dose-dependent inhibition of ex vivo platelet aggregation induced by ADP was achieved with iv infusions 0.1-10 μg/kg/min of 23m in anesthetized dogs, with 10 μg/kg/min completely inhibiting platelet aggregation during the entire 6 h infusion protocol.Platelet aggregatability returned rapidly after the termination of the 23m infusions.These features suggest that 23m may be useful in the treatment of arterial occlusive disorders.